
Pers Immune
Biotechnology, Sorrento Valley Rd, San Diego, , 92121, California, 11555, United States, 1-10 Employees
Phone Number: 85********
Who is PERSIMMUNE
PersImmune is a clinical-stage immunotherapy company whose mission is to provide cancer patients with optimized immunotherapy that is personalized on the basis of their own unique tumor s...
Read More

-
Headquarters: 11555 Sorrento Valley Rd, San Diego, California, 92121, United States
-
Date Founded: 2009
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8731
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from PERSIMMUNE
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding PersImmune
Answer: PersImmune's headquarters are located at Sorrento Valley Rd, San Diego, , 92121, California, 11555, United States
Answer: PersImmune's phone number is 85********
Answer: PersImmune's official website is https://persimmune.com
Answer: PersImmune's revenue is Under $1 Million
Answer: PersImmune's SIC: 8731
Answer: PersImmune's NAICS: 541714
Answer: PersImmune has 1-10 employees
Answer: PersImmune is in Biotechnology
Answer: PersImmune contact info: Phone number: 85******** Website: https://persimmune.com
Answer: PersImmune is a clinical-stage immunotherapy company whose mission is to provide cancer patients with optimized immunotherapy that is personalized on the basis of their own unique tumor signature. Just as no two people are alike, no two cancers are exactly alike; because of this, the same immunotherapy treatment that works for one patient may not work well in another. To address this treatment disparity, PersImmune's proprietary protocol, Personal Adoptive Cellular Therapy for Neoantigens (PACTN) identifies the DNA alterations present in the cancer cells of each patient and generates enriched, tested, highly-specific T-cells that effectively kill the patients tumor cells. These are the patient's own cells, and are not edited or genetically engineered which means patients will experience far less side effects than from chemotherapy or other methods of immunotherapy. Personalized adoptive cellular therapy has the potential to transform the field of cancer treatment by providing safe, highly-tolerable, effective immunotherapy to cancer patients. Personal immunotherapy - because no two patients are exactly alike. PersImmune is currently accepting patients for the Phase 1 clinical trial of its Personalized Adoptive Cell Transfer technology targeting Neoantigens (PACTN). The trial provides a therapy for early and late stage patients of myelodysplastic syndrome (MDS).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface

Sign in to CIENCE GO Data to uncover contact details
Free credits every month